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Abstract
Background: There are still some patients who show poor response to ovarian stimulation prior to evidence of
normal ovarian reserve in vitro fertilization. However, there are few studies about how to treat the unexpectedly
ovarian poor responder in vitro fertilization. The main aim of this study evaluate the effect of prolonging
administration follicle-stimulating hormone in woman with the unexpectedly ovarian poor responder in vitro
fertilization on implantation rate, clinical pregnancy rate and live birth rate.
Methods: 922 patients subjected to IVF were divided into two groups according to the predicted criterion of
ovarian poor response. 116 patients predicted poor response received the short protocol (group C). The others
received the long protocol, among the latter, there were 149 patients undergoing unexpectedly ovarian poor
response (group B) and 657 patients exhibited normal ovarian response (group A). The doses of gonadotropin,
duration of administration, implantation rate, clinical pregnancy rate and live birth rate were recorded among three
groups.
Results: The implantation rate of embryo, clinic pregnancy rate and delivery rate are similar between the group A
and group B, while there are significant differences between the doses of gonadotropins (35.1 +/- 8.9 ampules
vs.53.0 +/- 15.9 ampules) and the duration of administration (15.3 +/- 3.6D vs. 9.8 +/- 2.6D) of these two groups.
There are no significant differences about clinical pregnancy rate and live birth rate between group B and group C.
Conclusion: Prolonging administration gonadotropin on the unexpectedly poor ovarian responders does not
lower live birth rate in vitro fertilization.
Background
The success of in vitro fertilization (IVF) depends on
careful patient selection and adequate controlled ovar-
ian hyperstimulation. It is estimated that 5%-18% of all
IVF cycle are complicated by poor response to ovarian
hyperstimulation. Poor response to goandotropin may
result in reduction in the pool of embryos available for
transfer or cryoperservation, and decrease pregnancy
rates. There is still no consensus definition of poor
responder [1]. The following criterions had been used
to define “poor responders” in practice [2]: No. of
mature follicles <2-5; No. of mature oocytes retrieved
≤3; Single dominant follicle; Mean daily gonadoropin
dose ≥300 IU; Total gonadotropin dose >40 ampules
[3].
It is necessary to identify low responders prior to hor-
monal treatment for in vitro fertilization-embryo trans-
fer, so that the patients can be counseled regarding the
lower chances for pregnancy, more realistic expecta-
tions, and cautiously alternative therapies such as oocyte
donation or adoption. In addition, stimulation protocols
for these patients can be modified to lower the risk of
cancellation and improve pregnancy rates. As a result,
many screening methods have been proposed to assess
prospectively ovarian reserve and individualize treatment
regimens. Ovarian reserve decline has been proved to
related to age, hormone screening tests, the number of
antral follicles, basal ovarian volume, and the result of
their previous IVF/HCG treatment.
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although there is no suggestive evidence of low ovarian
reserve in IVF [4]. There are few literatures about how
to deal with unexpectedly poor ovarian response in
order to increase the number of oocytes retrieved, lower
cyclical cancellation rate, and improve the IVF result.
The aim of this study is to evaluate whether prolonging
administration FSH in unexpectedly poor ovarian
responders could cut down cancellation rates and attain
ideal pregnancy rates.
Methods
Study design
This is a retrospective analysis of prolonging administra-
tion gonadotropin on unexpectedly ovarian poor respon-
ders undergoing fresh IVF/ICSI cycles at the
reproductive center of the first affiliated hospital of
Anhui medical university. In a review of our electronic
database, we found 149 patients who have unexpectedly
ovarian poor response during in vitro fertilization
between Jan 2005 and Dec 2006. Controls were matched
for the data of that included: IVF procedure, age, basal
antral follicle count, basal FSH, infertility diagnosis and
intracytoplasmic sperm injection (ICSI) or conventional
insemination. The analysis was approved by the Institu-
tional Review Board (IRB) of Affiliated Hospital of
Anhui Medical University. The main outcome is com-
prised of the live-birth rate per cycle. Other outcomes
are the number of duration of gonadotropin therapy,
ampules of gonadotropin, number of oocytes retrieved,
clinical pregnancy rates and pregnancy loss rates.
Patients
The study was carried out between Jan 2005 and Dec
2006 in the reproductive center of the first affiliated hos-
pital of Anhui medical university. A diagnosis of poor
responders was made if patients matched the following
criteria: age >38 y, serum basal FSH over 10 IU/ml, basal
antral follicle counts (BAFC) ≤5. According to the pre-
dicted criterion of ovarian poor response, 922 patients
subjected to IVF were divided into three groups. 116
patients with predicted poor response received the flare-
up GnRH agonist protocol (group C);The others received
the GnRH agoinst long protocol. Among the latter, 657
patients were normal ovarian response (group A), how-
ever there were 149 patients with unexpectedly ovarian
poor response (group B). Here unexpectedly ovarian
poor responders were defined using the following criter-
ion [5]: the duration of gonadotropin administration ≥ 14
d and the doses of gonadotropin >40 ampules.
Ovarian stimulation
Patients in group A and group B received muscular
injections of 1.87 mg luteal gonadotropin-releasing
hormone (GnRH, leuprolide acetate) in the midluteal
phase of the previous cycle. Two weeks later, FSH
(Gonal-F, Serono) was administered at an initial dose of
225 IU per day. The FSH dosage was modified accord-
ing to the ovarian response monitored by serial transva-
ginal scanning after 5 days. In group C, patients were
stimulated with a short protocol using down-regulation
by GnRH from day 2 of the cycle (leuprolide acetate
1.87 mg) and muscular injection of FSH (Gonal-F, Ser-
ono) at a dose of 225 IU from day 5 of the cycle. The
FSH dosage was adjusted according to the ovarian
response monitored by serial transvaginal scanning after
7 days of stimulation. Oocyte retrieval was performed by
transvaginal aspiration approximately 36-40 h after
injection 10 000 IU of human chorionic gonadotrophin
(HCG, Lizhu, China) intramuscularly (IM) when two or
more follicles reached >18 mm. Insemination take
placed by standard IVF or ICSI.
Embryo transfer technique
Embryo transfers were performed 3 days after oocyte
retrieval using a flexible catheter (Wallance, Smiths
Medical Internation, UK). The number of embryos
transferred was 2-3. The cervical canal was cleaned with
warmed culture media before transfer. Luteal support
was starting from the day of “ICSI” untill 12 weeks of
gestation with 60 mg Progesterone (Xianju, China) by
intramuscular injection daily. Urinary HCG test was per-
formed on day 15 after embryo transfer to confirm
pregnancy. Clinical pregnancy was determined when a
gestation sac was seen by transvaginal ultrasound at
5 weeks after embryo transfer.
Statistical analysis
The SPSS12.0 package was used for statistical analyses.
Data were expressed as means ± SD. Students t and chi-
square tests were used when appropriate and P < 0.01
was considered statistically significant.
Results
Baseline characteristics of women
Patient characteristics of the two different stimulation
protocols are presented in Table 1. The mean ages of
group A and group B are similar. There were no notice-
able differences in body mass index (BIM) neither, as
well as in basal serum FSH and E2, basal antral follicle
counts and endometrial thickness on the day of oocytes
retrieval between two groups. Basal serum FSH has
statistically differences between group A and group C
(6.12 ± 2.49 IU/L vs. 7.92 ± 2.88 IU/L, P < 0.01).
Gonadotrophin administration of three groups
There were significant differences among the doses of
gonadotrophins (35.09 ± 8.96 ampules vs. 52.97 ± 15.93
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2.60D vs. 15.34 ± 3.56D, p < 0.01) between group A and
group B. In group A, the number of oocytes retrieved
was higher than that in group B (16.09 ± 7.95 vs.13.72 ±
9.19, P > 0.01). Further more, the doses of gonadotro-
phins (2.97 ± 15.93 ampules vs. 38.13 ± 16.14 ampules)
and the duration of administration (15.34 ± 3.56D vs.
9.78 ± 2.60D) were statistically different between group
B and group C (p < 0.01). The number of oocytes
r e t r i e v e dw a sf o u n dt ob es i g n i f i c a n t l yi n c r e a s e di n
group B compared with group C (7.57 ± 5.25 vs.13.72 ±
9.19, P < 0.01). (Table 1)
Comparison of treatment outcomes
As summarized in Table 2, clinical pregnancies, embryo
cleavage, good embryo quality and implantation rates
were comparable in groups A and groups B, but we
observed no significant different about embryo implan-
tation (20.8% vs.20.1%, P > 0.01), clinical pregnancies
rates (34.3% vs.31.9%, P > 0.01) and live birth rate
(23.6% vs. 22.5%) between these two groups. Fertiliza-
tion and embryo cleavage rates were similar in the
group A and group C (P > 0.01), while there were sig-
nificant differences among good embryo quality rate
(89.4% vs. 67.8% P < 0.01), implantation rate (20.8%
vs.16.5% P < 0.01) and clinical pregnancy rate(34.3% vs.
21.6%, P < 0.01). But clinical pregnancy rate and live
birth rate was comparable for women in groups B
and C.
Discussion
Our data show that the live-birth rate of prolonging
administration FSH on the unexpectedly poor ovarian
responders with normal FSH responsiveness during IVF
cycles was similar. The results indicated indirectly that
administration FSH in long time does not impair
oocytes and embryos quality.
Ovarian stimulation protocols aim to enhance follicu-
lar recruitment and avoid spontaneous ovulation. Select-
ing the appropriate ovarian stimulation protocol and
controlling the dose of gonadotrophin, not only can
obtain the best curative effect but also reduce the risk of
poor ovarian response and ovarian hyperstimulation
syndrome. Assessment of ovarian reserve in women
undergoing assisted reproduction is useful in optimizing
the treatment protocol and in counselling the patients.
Poor responder was predicted by the presence of the
following characteristics [6]: age >35 y; basal serum FSH
level (bFSH ) >8 IU/ml, or FSH/LH ≥3; the basal
volume of each ovary <3 ml, the number of antral folli-
cle <6; basal serum inhibin B level <45 pg/ml. In
assisted reproduction programs, the response of “good
responders” or “poor responders” to exogenous FSH is
individualized and the ovarian response to intense gona-
dotrophin stimulation is difficult to predict. The
response of some patients will be poor though their
Table 1 Clinical information and basal hormonal profiles in three groups
A group B group C group P value
No. of patients 657 149 116 NS
Age (years) 30.6 ± 3.3 30.6 ± 3.4 38.5 ± 2.1 <0.01
Body mass index (kg/m
2) 20.3 ± 1.6 22.3 ± 1.7 21.4 ± 1.5 NS
BAFC 12.5 ± 2.1* 11.6 ± 3.2* 4.4 ± 1.9* <0.01
FSH (IU/L) 6.12 ± 2.9 6.72 ± 2.8 7.92 ± 2.9 <0.05
LH (IU/L) 4.6 ± 3.4 4.76 ± 3.3 4.50 ± 2.3 NS
Estradiol (nmol/L) 169.8 ± 131.2 183.10 ± 162.5 192.4 ± 144.1 <0.01
Endometrial thickness(mm) 11.8 ± 2.7 11.7 ± 2.6 10.93 ± 4.1 NS
Number of ampoules of Gn 35.1 ± 8.9 53.0 ± 15.9 38.1 ± 16.1 <0.01
Stimulation duration (days) 11.5 ± 1.2 15.3 ± 3.6 9.8 ± 2.6 <0.01
Peak E2 (nmol/L) 18672.3 ± 5462.4 16769.2 ± 7685.81 9734.8 ± 1245.5 <0.01
Oocytes retrieved 16.1 ± 7.9 13.7 ± 9.2 7.6 ± 5.3 <0.01
Embryos transferred 2.3 ± 0.6 2.3 ± 0.5 2.9 ± 0.7 <0.01
BAFC: basal antral follicle counts. Serum peak E2 was measured in injection HCG day. Values are reported as mean ± SD unless otherwise stated. P < 0.01 was
considered statistically significant
Table 2 Comparison of clinical outcome of three groups
A group
(n = 657)
B group
(n = 149)
C group
(n = 116)
P value
Insemination
rate (%)
73.3 72.4 79.94 NS
Embryo cleavage
rate (%)
90.6 87.2 93.1 NS
Good quality embryo
rate (%)
89.4* 86.7 67.8* <0.01
Embryo implantation
rate (%)
20.8* 20.1 16.5* <0.01
Clinical pregnancy
rate (%)
34.3* 31.9 21.6* <0.01
Abortion rate (%) 19.6 16.9 15.7 NS
Live brith rate (%) 23.6 22.5 15.0 NS
Note: * P < 0.01 was considered statistically significant
Wei et al. Reproductive Biology and Endocrinology 2010, 8:26
http://www.rbej.com/content/8/1/26
Page 3 of 5predictive tests were not being suggest low ovarian
reserve. The sensitivities varied for the prediction of
poor ovarian response varied between 39% and 97%,
and specificities between 50% and 97% [7]. At present,
we can’t accurately predict poor response in IVF/ICSI
cycles, there are still 16.16% cases in unexpectedly poor
ovarian response in our center.
Unexpectedly poor responders represent a heteroge-
neous group of patients. Different mechanisms have
been proposed to explain poor ovarian response such as
decreased number of FSH receptors in granulosa cells
[8], defective signal transduction after FSH-receptor
binding [9], anti-FSH IgA and IgG potentially exerting a
local FSH antagonizing effect in maturing follicles [10],
the presence of a specific FSH receptor-binding inhibitor
in the follicular fluid [11], the higher FSH threshold to
stimulation follicle development.
The most prevalent approaches for treating poor
responder are always the GnRH agonist flare protocol.
Compared to traditional long GnRH agonist protocol,
there is no significant difference in clinical pregnancy rates
[12,13]. Our data showed that increased doses of gonado-
tropins were not able to influence ovarian response in
poor responders (group C), the pregnancy rate for poor-
responder patients and number of oocytes retrieved are
lower than the two other groups (group A and group B).
GnRH antagonist may shorten the duration of stimu-
lation, lower the total gonadotropin requirements,
reduce patient’s cost, decrease cycle cancellation, and
has a higher ongoing pregnancy and a better delivery
rate in poor responder patients [14,15]. There is a new
method to use GnRH antagonist before ovarian stimula-
tion in order to lengthen the follicle phase and rescue
more follicles. Doing so, more oocytes and zygotes were
attained, implantation rate and ongoing pregnancy rates
were improved [16]. Addition of LH may be beneficial
effect in poor ovarian responders [17,18], but other pro-
spective and randomized trial show that the addition of
rLH to the ovarian stimulation protocol produces no
further benefit in older poor responder patients [19].
Endogenous FSH in the preceding luteal phase can sti-
mulate larger follicles and subsequently lead to a size
discrepancy. A novel strategy for treating poor respon-
ders is to give estradiol in the luteal phase before IVF
hyperstimulation, the estradiol can suppress FSH in the
preceding luteal phase and result in more coordinated
cohort of follicles responding to the stimulation process.
The luteal E2 protocol may improve embryo quality and
delivery rates [20-22]. There is few study about treat-
ment on the women in unexpectedly poor ovarian
responders in IVF cycle. Pretreatment with transdermal
testosterone may improve ovarian response to gonado-
trophins and ovarian sensitivity to FSH in low-responder
IVF patients with normal basal concentration of FSH
and in previous low- responder IVF patients [23,24].
Our study showed that prolonging to administration
FSH on the unexpectedly poor ovarian responders only
reflect a decreased number of oocytes retrieved, But
clinical pregnancy loss rate and live birth rate were sim-
liar between group A and group B in the study. The
result is accordance with other reports [25]. Prolonging
to administration FSH on the unexpectedly poor ovarian
responders could raise financial burden to couples, but
reduce the psychological distress related to cycle
cancellation.
Conclusions
Prolonging administration FSH on the unexpectedly
poor ovarian responders could increase number of
oocytes retrieved, reduce number of cancelled cycles
and improve IVF outcomes. Future studies would be
helpful to reveal the mechanism so that stimulation pro-
tocols for these patients can be modified to lower the
risk of cancellation and improve pregnancy rates.
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